A Shingles Shot and the Dementia Question

Most of what we write about brain health asks something of you. Walk a bit more. Sleep a bit better. Sit down with a puzzle. This one is different, because the thing being studied is something you might already have on a list somewhere, half-forgotten, under the heading of ordinary adult admin.

A study published in Annals of Internal Medicine in August 2026 looked at the shingles vaccine and dementia diagnoses. The researchers, led by Kaleen Hayes at Brown University's School of Public Health, found that older adults who had received the vaccine were 24 percent less likely to be diagnosed with dementia over the following four years.

What the study actually did

The team used American Medicare claims and electronic health records covering 509,926 adults aged 66 and over, all of whom had been admitted to one of more than 5,500 skilled nursing facilities between 2017 and 2022. Everyone included was eligible for shingles vaccination and had no previous dementia diagnosis.

Of those half a million people, 8,843 received at least one dose of the recombinant shingles vaccine, known as Shingrix or RZV. The rest did not. Four years later, dementia had been diagnosed in 18.8 percent of the vaccinated group and 24.6 percent of the unvaccinated group.

The researchers describe that gap as roughly one dementia case potentially avoided for every seventeen people vaccinated. That is a striking way to put a number, and it is worth holding it lightly for reasons we come to below.

To analyse the data they used a method called target trial emulation, which tries to recreate the conditions of a randomised trial using records from the real world, in situations where running the actual trial is not practical. It is a serious technique. It is not the same thing as a trial.

Why this is not the first time

What makes the finding interesting is that it did not arrive alone. Several earlier studies, including a much-discussed natural experiment in Wales where a vaccination cutoff date effectively sorted people into two groups by birthday, found the same direction of effect with an older shingles vaccine. This new work is the first large look at Shingrix specifically, in a frail population, at a clear clinical moment.

A single surprising result is a curiosity. The same result appearing repeatedly, in different countries and study designs, is the beginning of a pattern. Researchers are cautiously interested in why that pattern might exist — whether preventing a viral reactivation also prevents some of the inflammation that damages the brain over years. Nobody has shown that mechanism yet.

The honest limits

This study cannot tell us that the vaccine caused the lower dementia rate. The authors say so themselves, and it matters more here than usual.

People who get vaccinated are, on average, different from people who do not. In this study the vaccinated group tended to be slightly younger and in somewhat better health to begin with — and better health is itself linked to lower dementia risk. The researchers adjusted their analysis for those differences and found the association survived, but statistical adjustment can only correct for the things that were measured. Something unmeasured, like the general tendency to seek out preventive care, could be doing part of the work.

There is a second thing you should know. The authors received funding from GlaxoSmithKline, which makes Shingrix. They state that the company had no role in the study design, the analysis, or the decision to publish. That disclosure is how science is supposed to work, and it is also a reason to want independent replication.

Finally, this was a population of adults entering skilled nursing care. Whether the same association holds for a healthy sixty-year-old living independently is genuinely not known.

So: an association, in one population, consistent with earlier associations, with a plausible but unproven mechanism. Randomised trials will be needed before anyone can say the vaccine protects the brain.

What to do with this

Nothing dramatic. The shingles vaccine already has a clear reason to exist: shingles itself is painful, sometimes seriously so, and the vaccine prevents it well. If you are over fifty and have not had the conversation with your doctor, this is a reasonable prompt to have it — for the shingles protection, with the possibility of a brain benefit as an open question rather than a promise.

That is the whole recommendation. Ask your doctor. They know your history, and this is their decision to make with you, not ours.

The part you can control today

What we find quietly encouraging about this line of research is what it implies rather than what it proves: that brain health is not a separate department from the rest of your health. Blood pressure, hearing, sleep, infections, movement — the brain sits downstream of all of it.

Treeny is built on the same idea, at a smaller scale. A short daily session, a few minutes of focused thinking, with Flo adjusting the difficulty so the exercises stay interesting rather than either frustrating or dull. It is one ordinary habit among several, not a substitute for any of them.

A note

This article is general information, not medical advice. It describes one study and what it does and does not show. Decisions about vaccination, or about anything else concerning your health, belong with a qualified healthcare professional who knows your situation.